Jerini AG was a pharmaceutical company based in Berlin, Germany, which focused on the discovery and development of novel peptide-based drugs.

Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist.

[citation needed] Jerini's lead compound Firazyr (icatibant), is an inhibitor of the action of the hormone bradykinin on its B2 receptor.

[5] Based on its P2D platform, Jerini established several in-house development programs, to address indications within the ophthalmology, oncology, and inflammatory therapeutic areas.

The most advanced of these programs targeted age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries.